NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

A Prospective Natural History Study of VHL Patients with CNS Hemangioblastomas

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

00-N-0140

Sponsoring Institute

National Institute of Neurological Disorders and Stroke (NINDS)

Recruitment Detail

Type: No longer recruiting/follow-up only
Gender: Male & Female
Min Age: 8
Max Age: 75

Referral Letter Required

No

Population Exclusion(s)

None

Special Instructions

Currently Not Provided

Keywords

Brain;
Brainstem;
Cysts;
Spinal Cord;
MRI (Magnetic Resonance Imaging)

Recruitment Keyword(s)

None

Condition(s)

Hemangioblastoma;
Hippel Lindau Disease

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

None

Supporting Site

National Institute of Neurological Disorders and Stroke

The purpose of this study is to learn more about the growth of brain and spinal cord tumors and cysts that develop in association with them in patients with von Hippel-Lindau disease. It will examine how fast the tumors grow and try to determine what factors (for example, puberty , pregnancy, menopause, blood proteins, etc.) affect their growth.

Patients between the ages of 8 and 75 years who are enrolled in NIH s study of von Hippel-Lindau disease may be eligible for this 5-year study. Participants will have magnetic resonance imaging (MRI) of the brain and spinal cord and a thorough neurological history and examination at the start of the study. A blood sample will be taken for analysis of factors (hormones or other proteins) that may predict tumor growth. Follow-up clinic visits every 6 months will include a physical and neurological examination, blood tests, and MRI scans of the brain and spine. If symptoms or tumor growth requires more frequent follow-up, scans will be done at 3-month intervals.

Surgical removal of brain and spinal cord tumors is currently the treatment of choice when these lesions cause neurological problems. A better understanding of which tumors are likely to grow and which will remain stable may help guide physicians in treatment decisions and avoid unnecessary procedures.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

1. Ages 8-75.

2. Confirmed diagnosis of von Hippel-Lindau disease.

3. Presence of one or more cerebral, cerebellar or spinal cord hemangioblastomas on screening MRI.

4. Able to give informed consent (or assent), or have a parent able to provide informed consent if a child.

5. Karnofsky Performance Scale Score greater than or equal to 60.

6. Have the capacity to undergo serial MRI scanning of the CNS without IV sedation.

EXCLUSION CRITERIA:

1. Clinically unstable condition.

2. Being treated by any chemotherapy, immunotherapy, or steroids.

3. Allergy to CT or MRI contrast agents.

4. Contraindication to MRI scanning such as surgery that involves metal clips or wires which might be expected to cause tissue damage or produce image artifacts.


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Prashant Chittiboina, M.D.
National Institute of Neurological Disorders and Stroke (NINDS)



Gretchen C. Scott, R.N.
National Institute of Neurological Disorders and Stroke (NINDS)
National Institutes of Health
Building 10
Room 3D20
10 Center Drive
Bethesda, Maryland 20892
Not Listed
SNBrecruiting@nih.gov

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: 1-866-411-1010
PRPL@cc.nih.gov

Clinical Trials Number:

NCT00005902

--Back to Top--